Search - tctmd.com

Displaying 301 - 320 of 1360

Sort: Relevancy | Date

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

News Daily News

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

Yael L. Maxwell

December 20, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

COVID-19: TCTMD’s Dispatch for November Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 4

November 22, 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

News Conference News AHA 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

November 19, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Fitbit Joins the AF Hunt, but Effect on Treatment, Outcomes Unknown

News Conference News AHA 2021

Fitbit Joins the AF Hunt, but Effect on Treatment, Outcomes Unknown

Yael L. Maxwell

November 14, 2021

PALACS: Posterior Left Pericardiotomy Cuts Postop AF After Cardiac Surgery

News Conference News AHA 2021

PALACS: Posterior Left Pericardiotomy Cuts Postop AF After Cardiac Surgery

November 14, 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

News Conference News AHA 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

November 14, 2021

What About Anticoagulation Alone?

Presentation TCT 2021

What About Anticoagulation Alone?

Presenter: Teresa Carman

November 06, 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

News Conference News TCT 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

Yael L. Maxwell

November 06, 2021

Oral Anticoagulation Should Be the Default Strategy After LAAC

Presentation TCT 2021

Oral Anticoagulation Should Be the Default Strategy After LAAC

Presenter: Matthew J. Price

November 06, 2021

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presentation TCT 2021

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Connie Hess

November 06, 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

November 06, 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

November 05, 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

November 05, 2021

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

Presentation TCT 2021

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

Presenter: Pavel Osmancik

November 05, 2021

Controversies Surrounding Transcatheter Devices: Durability, Anticoagulation, Conduction, and More

Presentation TCT 2021

Controversies Surrounding Transcatheter Devices: Durability, Anticoagulation, Conduction, and More

Presenter: Josep Rodés-Cabau

November 04, 2021

TCT 703: Concomitant Transcatheter Mitral-Valve-in-Valve (MViV) with Left Atrial Appendage (LAA) Occlusion Device in a High-Risk Patient Unable to Tolerate Anticoagulation

Presentation TCT 2021

TCT 703: Concomitant Transcatheter Mitral-Valve-in-Valve (MViV) with Left Atrial Appendage (LAA) Occlusion Device in a High-Risk Patient Unable to Tolerate Anticoagulation

Presenter: Peter Sayegh

November 04, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.